Clinical Trial Update: Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating natalizumab for preventing postpartum relapses in multiple sclerosis has completed. Results were posted on 2025-01-22.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: State University of New York at Buffalo | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2025-01-22